ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Bristol-Myers Gets SEC Subpoena In Foreign Bribery Probe

By Peter Loftus Of DOW JONES NEWSWIRES Drug maker Bristol-Myers Squibb Co. (BMY) said it has received a subpoena from the U.S. Securities and Exchange Commission as part of an investigation into bribery overseas. Bristol-Myers said the subpoena received in March seeks information related to sales and marketing practices in "various countries." The New York-based company said in a quarterly report filed Thursday with the SEC that it was cooperating with the government. A spokeswoman declined comment beyond the information in Thursday's SEC filing. Bristol-Myers, which sells the anti-clotting drug Plavix, previously disclosed that the SEC was investigating the activities of the company's units in Germany, concerning potential violations of the U.S. Foreign Corrupt Practices Act, or FCPA. U.S. authorities in recent years have stepped up enforcement of the FCPA, which bars U.S. companies from bribing foreign officials to obtain or retain business. Multinational drug and medical-device makers based in the U.S. have been among the targets of enforcement. Last year, Johnson & Johnson (JNJ) agreed to pay nearly $80 million to resolve allegations that it paid bribes to doctors in three European countries, as well as kickbacks to Iraq to illegally obtain business under former leader Saddam Hussein. Other drug makers--including Pfizer Inc. (PFE), Merck & Co. (MRK) and Eli Lilly & Co. (LLY)--also have been the subjects of federal inquiries regarding the FCPA. -By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
03/30/201509:18:40OncoSec Medical Has A Promising Technology
03/30/201506:02:37Berkshire Hathaway Is Terrific - Cramer's Lightning Round (3/27/15)
03/29/201510:02:03Is Gilead Sciences Inc. About to Crater Before Our Very Eyes?
03/29/201503:44:43Merck: Buyback Plan Not As Impressive As It Appears
03/28/201514:02:03Out of 12 Big Pharma Stocks, This is the 1 You Can Confidently...
03/27/201509:19:49Ebola vaccine candidates pass safety test in in Liberia trials
03/27/201508:00:00Merck to Hold First-Quarter 2015 Sales and Earnings Conference...
03/27/201507:58:02Is This Tiny Biotech Still a Buy at All-Time Highs?
03/26/201508:30:00Merck Announces Collaboration with the American Diabetes Association...
03/25/201519:09:32Investors Scoop Up Companies' Bonds
03/25/201508:48:22Merck's Dividend Has Recovered From Pre-Recession Problems
03/25/201506:30:55Wall Street Breakfast: Kraft, Heinz Announce Mega Merger
03/24/201517:58:29Merck Increases Buyback Authorization by $10 Billion
03/24/201517:00:00Merck Announces New $10 Billion Share Repurchase Program
03/24/201509:08:25Merck's Keytruda tops Bristol-Myers' Yervoy in melanoma trial
03/24/201508:30:00Merckâs Pivotal KEYNOTE-006 Study in First-Line Treatment for A...
03/22/201511:01:043 Things You Need to Know About Achillion Pharmaceuticals Inc.
03/21/201508:11:01Why Pfizer Inc. Isn't Built to Last
03/20/201510:02:00Award-Winning Actress S. Epatha Merkerson and Merck Challenge...
03/18/201516:19:00New Data Investigating Merckâs KEYTRUDA® (pembrolizumab) in Ad...

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad